Association of blood DPP5 level with cancer type, stage, and survival

2010 2010

Other formats: Order a copy

Abstract (summary)

Introduction. Membrane-bound dipeptidyl peptidase 5 (DPP5) has been linked to tumor invasion and metastasis processes. Its recent isolation as a soluble protein from plasma may indicate a potential role as a biomarker and prognostic factor for tumors, and as a potential therapeutic target. This study aimed to measure the plasma levels of DPP5 and the related member of the family, DPP4, in healthy subjects and cancer patients, and to determine their clinical significance.

Methods. Enzyme-linked immunosorbent assays (ELISAs) for measuring plasma DPP5 and DPP4 were developed and clinical correlations were made.

Results. ELISAs were validated to be sensitive and specific. In the 747 plasma samples studied, mean DPP5 and DPP4 levels were 0.51±0.30 and 4.65±6.37 μg/mL, respectively. Plasma DPP5 levels were highly correlated with DPP4 levels. Plasma DPP5 and DPP4 levels were significantly lower in cancer patients compared with healthy subjects (4.38 versus 5.65 μg/mL μg/mL, p<0.001 for DPP4; 0.46 versus 0.66 μg/mL, p<0.001 for DPP5). DPP5 and DPP4 levels were higher in younger patients and those with earlier-stage cancers, but also in metastatic cancers; stage III cancer patients had the lowest plasma levels. Cancer patients with low DPP4 levels had shorter survival than those with higher DPP4 levels (p=0.001). There was also a trend toward shorter survival in cancer patients with low DPP5 levels in various cancer types, with the exception of colorectal cancers. An in vitro model indicated that approximately 80% of DPP5 released from the cells into conditioned medium is free (not associated with membranes), and serine protease inhibitors interfere with release of DPP5 into medium.

Conclusions. This study demonstrates that plasma DPP5 and DPP4 levels are reproducible parameters to correlate with disease status, with lower levels noted in cancer patients compared with healthy subjects; but higher levels in metastatic cancers compared with non-metastatic cancers. These findings support a prognostic role for plasma DPP5 and DPP4 levels and they should be considered in attempts to use DPP5 as a therapeutic target to hinder cancer progression. An explanation of low levels of plasma DPP5 in cancer despite previously-reported high level of local expression remains to be determined.

Indexing (details)

Molecular biology;
0307: Molecular biology
0992: Oncology
Identifier / keyword
Health and environmental sciences; Biological sciences; Blood; Cancer; Dpp4; Dpp5; Prognosis; Seprase; Survival
Association of blood DPP5 level with cancer type, stage, and survival
Javid Roozi, Mazyar
Number of pages
Publication year
Degree date
School code
DAI-B 71/10, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
Chen, Wen-Tien; Fleit, Howard B.
Committee member
Simon, Sanford R.; Zucker, Stanley H.
State University of New York at Stony Brook
Molecular and Cellular Biology
University location
United States -- New York
Source type
Dissertations & Theses
Document type
Dissertation/thesis number
ProQuest document ID
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.